News BMS adds to IBD pipeline with $1.9bn GentiBio deal Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).
Events Partner Content 4th Treg Directed Therapies Summit 2022 See the full potential of Treg therapies
News Rezzayo antifungal okayed as Candida auris rings alarm bells Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK